Augmedix Inc
NASDAQ:AUGX
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
US |
Augmedix Inc
NASDAQ:AUGX
|
140.5m USD | -9.3 | ||
US |
Veeva Systems Inc
NYSE:VEEV
|
32.6B USD | 36.8 | ||
US |
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 32.2 | ||
US |
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | -171.1 | ||
JP |
M3 Inc
TSE:2413
|
1.3T JPY | 20.5 | ||
AU |
Pro Medicus Ltd
ASX:PME
|
11.7B AUD | 181.3 | ||
US |
Inspire Medical Systems Inc
NYSE:INSP
|
7.1B USD | 6 962.9 | ||
US |
Doximity Inc
NYSE:DOCS
|
4.5B USD | 28 | ||
SE |
Sectra AB
STO:SECT B
|
42.9B SEK | 141.7 | ||
US |
Evolent Health Inc
NYSE:EVH
|
3.2B USD | 12 | ||
US |
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.8B USD | 40.8 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.